Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zeldana is a prescription-grade dietary supplement developed by Misemer Pharmaceutical, specifically formulated to provide comprehensive nutritional support. It is an oral multivitamin and mineral supplement that includes bioavailable forms of essential nutrients, such as levomefolate calcium (L-methylfolate), methylcobalamin (Vitamin B12), and cholecalciferol (Vitamin D3). Zeldana is indicated for the clinical management of patients with specific nutritional requirements that cannot be met through normal diet alone, often used under medical supervision to address deficiencies or increased physiological demands. Its mechanism of action involves the exogenous replenishment of micronutrients that serve as essential cofactors for metabolic enzymes, support cellular DNA synthesis and repair, and maintain systemic homeostasis. The inclusion of L-methylfolate is particularly significant as it bypasses the metabolic steps required for the activation of folic acid, making it suitable for patients with genetic polymorphisms in the MTHFR enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zeldana.